✦ LIBER ✦

6105 POSTER Phase II Trial of Temsirolimus Alone and in Combination With Irinotecan for KRas Mutant Chemotherapy Resistant Metastatic Colorectal Cancer and the Importance of KRas Mutations in the Plasma

✍ Scribed by Spindler, K.G.; Sorensen, M.; Pallisgaard, N.; Andersen, R.F.; Lassen, U.; Havelund, B.M.; Ploen, J.; Jakobsen, A.

Book ID: 122543891
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 41 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(11)71750-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of KRAS and BRAF Gene Mutation St

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

✍ Price, T. J.; Hardingham, J. E.; Lee, C. K.; Weickhardt, A.; Townsend, A. R.; Wr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 273 KB

6096 POSTER FOLFOXIRI (Irinotecan, Oxali

6096 POSTER FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status – a Phase II Study by the G.O.N.O. Group

✍ Fornaro, L.; Loupakis, F.; Lonardi, S.; Masi, G.; Salvatore, L.; Cremolini, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB